Severe asthma treatment sales will rise through 2036, driven by anti-inflammatory drugs at 46.8% of the drug class in 2026. The market was valued at USD 24.32 billion in 2025 and is expected to be worth USD 42.0 billion by 2036, creating an incremental opportunity of USD 16.46 billion.